J., Pinkerton, J., Rymer, J., Simon, J
FDA-approved peptides (Saxenda, Wegovy, Zepbound) cause gastrointestinal side effects like nausea, vomiting and diarrhea in up to 80% of patients, with rare serious events including gallstones or inflammation of the pancreas
These are mechanisms described in published studies of the molecule, not human-use guidance Semaglutide is supplied for research only
Individuals with polycystic ovary syndrome often experience absent or irregular periods, ovarian cysts, infertility, facial hair growth, acne, weight gain, problems with blood sugar metabolism, and may have increased cardiovascular disease risk
FDA-approved semaglutide is tested for safety and effectiveness
Weiss, T